Needham & Company Downgrades Cardiovascular Systems (CSII) to Buy
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
Needham & Company downgraded Cardiovascular Systems (NASDAQ: CSII) from Strong Buy to Buy with a price target of $18.00 (from $37.00).
Analyst Mike Matson commented, "We are downgrading CSII to Buy from Strong Buy after last night's negative preannouncement. On one hand, we see few catalysts in the near term that could drive shares higher and we think there is a risk that shares could decline further into year-end given window-dressing and tax-loss selling. On the other hand, we believe CSII shares are undervalued, we remain believers in CSII's orbital atherectomy technology, and we see increased potential for a larger firm to acquire CSII given its depressed price. Considering these offsetting positives and negatives leads us to move to a Buy rating."
Shares of Cardiovascular Systems closed at $16.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China Said to Weigh Asking After-School Tutors to Go Non-Profit - Bloomberg
- Hanssem Co. Ltd. (009240:KS) PT Raised to KRW150,000 at Goldman Sachs
- Samhallsbyggnadsbolaget (SBBB:SS) PT Raised to SEK45 at Goldman Sachs
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades
Related EntitiesNeedham & Company, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!